Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms

CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal ...

Major depressive disorder shares immune abnormalities and potential therapies with inflammatory skin diseases

A team of leading clinical research scientists from the Departments of Psychiatry and Dermatology at the Icahn School of Medicine at Mount Sinai has found that the serum of patients with major ...
clinicaladvisor.com

How Does Major Depressive Disorder Affect Other Conditions in Patients?

Researchers found that 8.3% of US adults had at least one major depressive episode. In adolescents, the rate was 20.1%, with 29.2% of female adolescents reporting a major depressive episode. Major ...
European Medical Journal

Major Depressive Disorder Shares Immune Signature with AD

Major depressive disorder is linked to Th2 immune dysregulation similar to atopic dermatitis. Could dupilumab offer a new ...

Single dose of a psychedelic drug can rapidly reduce depressive symptoms, clinical trial suggests

A single dose of the psychedelic drug dimethyltryptamine (DMT), given with psychological support, rapidly reduced depressive ...

Single Dose of DMT Rapidly Reduces Symptoms of Major Depression

"A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, ...
Healio

Smoking, high BMI drive relationship between PAD, major depressive disorder

Please provide your email address to receive an email when new articles are posted on . Genetic major depressive disorder was linked to genetic liability for PAD. The association between genetic ...